Sign in
CLDX Stock Price, Chart, Stats & News
Celldex Therapeutics, Inc.
Save
2.25B
Market cap
–
Current P/E
–
Forward P/E
CLDX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 100.00% |
Operating margin | -19160.00% |
Pretax margin | -17253.33% |
Net margin | -17253.33% |
Effective tax rate | – |
ROA | -44.39% |
ROE | -41.68% |
D/E | 0.00x |
Interest coverage ratio | – |
CLDX valuation
P/E | – |
P/S | 1344.64x |
P/B | 3.82x |
P/CF | -9.55x |
P/FCF | -9.45x |
P/OCF | -9.55x |
PEG | 0.51x |
EV multiple | -7.35x |
About
Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. Their pipeline features therapeutic candidates aimed at both inflammatory conditions and various forms of cancer. Among their key clinical programs: CDX-0159 is a Phase I monoclonal antibody designed to bind to and inhibit the activity of the KIT receptor tyrosine kinase.
Similar securities
Based on sector and market capitalization
Report issue